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AbstrAct 
ObJECTIvE: measurement of urinary lh (ulh) and FSh (uFSh) may facilitate non-invasive 
pubertal assessment but there is a need for further validation by studying children and adoles-
cents with disorders of puberty. DESIgN: 65 cases (male: 25) with a median age of 12 years 
(2.9-18.1) supplied at least one non-timed urine sample for uLH and uFSH measurement by 
immunoassay and corrected for creatinine excretion. 25 cases were receiving gnRh-agonist 
(gnRh-a) at the time of sample collection. In 41 cases, urine samples were collected prior to a 
lhRh test and in 12 cases matched serum samples for basal lh (slh) and FSh (sFSh) were 
also available. RESUlTS: There was a significant correlation between slh and ulh:uCr 
(r=0.82; p-value <0.001) and sFSH and uFSH:uCr (r=0.93; p-value <0.001). Based on receiver 
operator characteristics analysis, a ulh:uCr value of 0.05 IU/mmol as a cut-off would detect 
a lh peak >5U I/l with a sensitivity of 86% and a specificity of 72% with a positive predictive 
value of 93%. In pubertal boys (6) and girls (22) with a sLH peak >5UI/L, median uLH:uCr was 
0.27 IU/mmol (0.27-0.28) and 0.17 IU/mmol (0.09-0.43), respectively. The median uFSH:uCr 
was 0.51 IU/mmol (0.41-0.60) for boys and 1.1 IU/mmol (0.21-2.44) for girls. In the 25 cases on 
gnRh-a, the median ulh:uCr for boys and girls was 0.02 IU/mmol (0.01-0.02) and 0.02 IU/
mmol (0.004-0.07), respectively, and the median uFSH:uCr was 0.07 IU/mmol (0.05-0.09) and 
0.27 IU/mmol (0.09-0.54), respectively. CONCLUSION: Urinary gonadotrophins reflect serum 
gonadotrophin concentration and may represent a reliable non-invasive method of assessing 
pubertal progress.
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INTRODUCTION
The onset of pubertal development and the pro-
gression to full maturity is due to activation of the 
hypothalamic-pituitary-gonadal (HPG) axis through an 
increase in gonadotrophin-releasing hormone (GnRH) 
pulsatility which leads to activation of the anterior 
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pituitary to produce gonadotrophins, luteinising hor-
mone (LH) and follicle-stimulating hormone (FSH).1 
Biochemical assessment of pubertal activation of the 
HPG axis requires multiple blood samples with the 
assessment of LH and FSH before and after stimu-
lation with GnRH-agonists (GnRH-a). These tests 
require a hospital visit and are expensive and inva-
sive. Gonadotrophin-dependent central precocious 
puberty (CPP) is often managed by suppression of 
the HPG axis through the use of GnRH-a that are 
administered as depot injections at fixed intervals.2 
Recently, a subcutaneous implant releasing the Gn-
RHa histrelin at an average rate of 65 microg/day 
was developed, with encouraging results.3,4 Moni-
toring of adequate suppression is usually based on 
an assessment of physical growth and puberty and 
the frequency of injections is often increased when 
these clinical parameters suggest inadequate sup-
pression. Although there may be scope for further 
personalization of therapy, this has been difficult to 
achieve in the absence of objective and reliable tools 
that are simple, inexpensive and lend themselves to 
repeat measurements. With improvements in assays 
and the increasing need for non-invasive, out-patient 
based investigations, there has been renewed interest 
in the use of urinary gonadotrophins (uGn) for as-
sessing pubertal progress. Recently, uGn have been 
reported to differentiate between healthy pre-pubertal 
and pubertal children.5,6 However, currently, there is 
a lack of evidence examining the utility of uGn for 
assessing disorders of puberty and for monitoring 
therapy that alters pubertal progress.
This study aims to investigate the relationship be-
tween serum (both basal and peak during the luteinis-
ing hormone releasing hormone (LHRH) stimulation 
test) and urinary LH (uLH) and FSH (uFSH) in young 
people undergoing investigation or management of 
pubertal disorders.
SUbJECTS aND mEThODS 
Subjects
Between December 2012 and July 2014, 65 cases 
with a median age of 12 years (age range 2.9-18.1) who 
were being evaluated for concerns regarding puberty 
at the Royal Hospital for Children, Glasgow, supplied 
a total of 117 non-timed spot urine samples as part 
of routine endocrine assessment. In 41 cases (Male: 
18), a urine sample was collected immediately prior 
to a LHRH stimulation test and in another 12 (Male: 
6) matched samples were also available for basal LH 
(sLH) and FSH (sFSH) determination. The 65 cases 
were referred for: early puberty (29), pubertal delay 
(27) [including constitutional delay (23) primary go-
nadal failure (2) and hypogonadotrophic hypogonadism 
(2)] and gender identity disorder (GID) (9) (Figure 1). 
A diagnosis of CPP, performed in 19 patients of those 
evaluated for early puberty, was based on a history 
of pubertal development at <8 years in girls and <9 
years in boys, clinical signs of pubertal activation 
(breast bud in girls, testicular volume >3 ml in boys) 
and a LH peak >5 IU/L on LHRH stimulation test. 
Early puberty was defined as clinical signs of pubertal 
activation but a stimulated LH peak <5 IU/L. Delayed 
puberty (DP) was considered in cases with no clinical 
and biochemical signs of pubertal activation in boys 
>14 years and in girls >13 years.7 In pubertal failure 
(hypogonadotrophic hypogonadism), a complete lack 
of response to LHRH stimulation test supported the 
diagnosis, while in primary gonadal failure, basal 
LH and FSH were elevated and their responses to 
LHRH were exaggerated. Samples were also col-
lected as part of routine endocrine monitoring in a 
group of adolescents with a psychiatric diagnosis of 
GID undergoing treatment with GnRH-a. Treatment 
to suppress puberty was performed with Triptorelin 
(Decapeptyl SR, Ipsen, UK) at a dosage of 11.25 
Figure 1. Main population characteristics. Age (years) at col-
lection of urine sample is expressed as median (range). Subjects 
were categorised according to the main reason for investigation 
of puberty.
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mg every 10 or 12 weeks. Among the 19 cases with 
CPP and 9 with GID, 25 received GnRH-a therapy 
between December 2012 and July 2014.
Anthropometry & imaging
Anthropometric measurements were performed 
by fully-trained examiners and converted into stand-
ard deviation score (SDS) using 1990 British chil-
dren standards.8 Height was measured to the nearest 
0.1 cm with a calibrated wall-mounted stadiometer 
(Harpenden, Crymych; UK) and weight was measured 
to the nearest 0.1-kg with a calibrated scale. Pubertal 
status was classified according to Tanner staging.9 
Bone age was assessed by x-ray of the left hand and 
wrist using BoneXpert (Visiana Aps, Denmark). In 
girls, pelvic ultrasound was performed to assess uterine 
length, fundo-cervical ratio, endometrial stripe and 
ovarian volume. Magnetic resonance imaging (MRI) 
of the brain and pituitary was performed in all cases 
with a diagnosis of CPP to exclude organic causes. 
An LHRH test was performed in 41 patients using 
a standard procedure, which consisted of collection 
of blood samples for serum LH and FSH estimation 
at baseline and 20 and 60 minutes after intravenous 
administration of 100 micrograms of LHRH (HRF, 
Intrapharm Laboratories Ltd, UK).
Gonadotrophin assays
Non-timed plasma and urine samples were col-
lected in the same period of the day, processed and 
stored at -20°C. Gonadotrophins were measured by a 
chemiluminescent microparticle immunoassay on the 
Architect ci8200 (Abbott Laboratories Diagnostics, 
IL, USA), as previously described.5 The lower limit 
of FSH and LH detection was 0.1 IU/L and inter- and 
intra-assay precision (coefficient of variation, CV) for 
both LH and FSH were less than 5% at levels of 0.2 
and 2.3 IU/L for LH and 0.6 and 4.7 IU/L for FSH. 
Analytical sensitivity of the assays was 0.07 IU/L and 
0.05 IU/L for LH and FSH, respectively. LH and FSH 
values <0.1 IU/L were attributed an arbitrary value 
of 0.1 IU/L to facilitate analysis. Urinary creatinine 
was measured using the modified Jaffe method with 
a lower limit quantitation of 0.35 mmol/L: none of 
the samples had a urinary creatinine <1.0 mmol/L. 
FSH and LH results were corrected for creatinine 
(by dividing the uGn value for the corresponding 
creatinine value of each urine sample) and compared 
to previously published reference data that were 
analysed following the same storage and analysis 
process.5 Effect of storage temperature was assessed 
by dividing a single urine sample into three groups of 
10 aliquots which where stored at room temperature 
(RT), 4°C or -20°C. A sample from each group was 
assayed for LH and FSH consecutively over 11 days. 
The CVs of the three groups for LH were 9.4%; 8.6% 
and 7.8% for samples stored at RT, 4°C or -20°C, 
respectively. For FSH, the CVs were 8.2%, 6.5% 
and 5.9% for samples stored at RT, 4°C or -20°C, 
respectively. Additionally, a urine sample was stored 
at -20°C and -70°C. Assays performed after 3 and 6 
months yielded LH levels that were 88% and 83% 
at -20°C and 89% and 86% of the original concen-
tration at -70°C. Similarly, yielded FSH levels were 
92% and 90% at -20°C and 94% and 91% -70°C of 
the original concentration.
Statistical analysis
All data were expressed as median (range) and 
analysed using SPSSv10.0 (SPSS Inc., Chicago, IL, 
USA). Inter-group comparison for continuous vari-
ables was performed with the Mann-Whitney U test 
and correlation between variables was determined 
using the Spearman’s correlation coefficient. A p-
value lower than 0.05 was considered statistically 
significant. Receiver operating characteristics (ROC) 
curves were performed for LH peak to select the cut-off 
value of uLH:uCr that provided a LH peak >5 IU/L. 
In the ROC curve, the true positive rate (sensitivity) 
was plotted as a function of the false positive rate 
(1-specificity) to identify the cut-off values of the 
parameter of interest.10 Sensitivity and specificity 
were calculated using the area under the ROC curve. 
RESUlTS
Correlation between urinary  
and serum gonadotrophins
In the 53 cases where there were matched urine and 
basal serum samples, there was a strong association 
between uLH:uCr and sLH (r=0.83, p-value<0.001) 
and uFSH:uCr and sFSH (r=0.93, p-value<0.001). 
After removing two outliers who had primary gonadal 
failure, the association between urine and serum con-
centrations for LH and FSH was 0.82 (p-value<0.001) 
and 0.93 (p-value<0.001), respectively (Figure 2). 
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In 41 cases who had a LHRH stimulation test, the 
optimal uLH:uCr cut-off point that predicted a LH 
peak greater than 5 IU/L was 0.05 IU/mmol with a 
sensitivity of 86% and specificity of 71%. The posi-
tive predictive value for a LH peak >5 IU/L when 
uLH:uCr was >0.05 IU/mmol was 93% (Figure 3). 
Pubertal delay
The median uLH:uCr for boys with pubertal delay 
was 0.12 IU/mmol (0.01, 0.48): this was significantly 
higher than the reference range for pre-pubertal boys 
at 0.01 IU/mmol (0.01, 0.2) (p-value=0.001) and 
within the reference range for pubertal boys (uLH:uCr 
0.09 IU/mmol (0.01, 0.28) (p-value=0.150). The 
median uFSH:uCr for the boys with pubertal delay 
was 0.44 IU/mmol (0.01, 9.9) and higher than the 
reference range for pre-pubertal boys at uFSH:uCr 
0.13 IU/mmol (0.004, 1) (p-value=0.003) and also 
for pubertal boys (uFSH:uCr 0.2 IU/mmol (0.02, 
0.7) (p-value=0.037). The median uLH:uCr for girls 
with pubertal delay was 0.09 IU/mmol (0.01, 1.37), 
higher than normal for pre-pubertal girls who had 
a median uLH:uCr of 0.013 IU/mmol (0.01, 0.08) 
(p-value=0.006) and within the reference range for 
pubertal girls who had a median uLH:uCr of 0.09 
IU/mmol (0.01, 1.1); (p-value=0.592). The median 
uFSH:uCr for girls with pubertal delay was 0.71 IU/
mmol (0.01, 16.1): these values were significantly 
Figure 3. ROC curve for analysis of uLH:UCr cut-off point that 
predicted a LH peak greater than 5 IU/L. In 41 cases who had a 
LHRH stimulation test, the optimal uLH:uCr cut-off point was 
0.05 IU/mmol with a sensitivity of 86% and specificity of 71%. 
The positive predictive value was 93%.
Figure 2. Correlation between serum gonadotrophins (sLH, sFSH) and urinary gonadotropins corrected for creatinine (uLH:uCr, 
uFSH:uCr). Significant associations were observed both for LH and FSH even after removing two outliers (two patients with primary 
gonadal failure referred for pubertal delay).
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girls with GID. The median uLH:uCr for girls with 
central puberty not on GnRH-a treatment was 0.17 
IU/mmol (0.02, 0.43) and significantly higher than 
the pre-pubertal reference range for pre-pubertal girls 
(p-value=0.010), but within the reference range for 
pubertal girls (p-value=0.418) (Figure 4). The me-
dian uFSH:uCr for girls with central puberty not on 
GnRH-a treatment was 1.09 IU/mmol (0.21, 2.44), 
significantly higher than the pre-pubertal reference 
range for pre-pubertal girls (p-value=0.021), but 
within the reference range for pubertal girls (Figure 
4). The ratio, uLH:uFSH, did not show a difference 
significant in females compared both to pubertal and 
pre-pubertal values.
True central puberty on GnRH agonist therapy
This group consisted of 17 cases of CPP (2 males, 
15 females) and 8 cases of GID (3 males, 5 female). 
The median uLH:uCr for boys and girls with true 
central puberty on GnRH-a treatment was 0.02 IU/
higher than the pre-pubertal reference range for pre-
pubertal girls [uFSH:uCr - 0.45 IU/mmol (0.2, 3.63)] 
(p-value=0.008) and within the reference range for 
pubertal girls (p-value=0.233) (Figure 4).
Early puberty 
There were 9 girls and 1 boy within this category. 
The median uLH:uCr for girls with early puberty 
was 0.03 IU/mmol (0.01, 0.49) and similar to the 
pre-pubertal (p-value=0.348) and pubertal (p-val-
ue=0.181) reference range for girls (Figure 4). The 
median uFSH:uCr for girls with early puberty was 
0.43 IU/mmol (0.11, 3.91), close to the pre-pubertal 
(p-value=0.167) and pubertal (p-value=0.768) reference 
range for girls (Figure 4). uLH:uFSH ratio showed 
no significant difference compared to pre-pubertal 
and pubertal values.
True central puberty 
This group consisted of 7 girls with CPP and 3 
Figure 4. Data are shown as logarithmic scale. Median values are represented by the solid bar. Overall, the median levels of UGn 
increased with pubertal development and decreased with pubertal suppression both for male and female.
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mmol (0.01, 0.02) and 0.02 IU/mmol (0.004, 0.13), 
respectively, significantly lower than the pubertal 
reference range for pubertal boys (p-value=0.002) 
and girls (p-value<0.001), but within the reference 
range for pre-pubertal boys and girls (Figure 4). 
The median uFSH:uCr for boys and girls with true 
central puberty on GnRH-a treatment was 0.07 IU/
mmol (0.05, 0.09) and 0.27 IU/mmol (0.12, 0.5), 
respectively, significantly lower than the pubertal 
reference range for pubertal boys (p-value<0.001) 
and girls (p=0.009), but within the reference range 
for pre-pubertal boys and girls (Figure 4). uLH:uFSH 
ratio showed a difference significant both in male and 
female compared to pubertal values.
DISCUSSION 
Disorders of puberty are commonly encountered 
in the field of endocrinology and its assessment rou-
tinely involves costly and invasive biochemical tests 
that require hospital attendance.11-14 Because of these 
limitations, children who undergo pharmacological 
pubertal suppression rarely undergo regular biochemi-
cal assessment of adequacy of the therapy. Whilst 
pubertal suppression by GnRH-a therapy is generally 
considered to be safe,15,16 it is possible that an improved 
knowledge of the extent of suppression may allow a 
more informed and customised treatment plan that is 
cheaper and more convenient for the child. Although 
measurement of uGn was described over four decades 
ago,17,18 its use in routine clinical management had 
not been considered until the relatively recent avail-
ability of more sensitive assays.3,4,14
In this study of cases that were undergoing routine 
evaluation of puberty, the addition of uGn assess-
ment has provided promising information regarding 
the clinical utility of this test for assessment and 
management of pubertal disorders. In a previous 
study aimed at creating reference ranges for healthy 
children,5 the lack of matched serum samples was 
considered to be a weakness and in the current study, 
the close correlation between uGn excretion and se-
rum gonadotrophins in a range of conditions related 
to pubertal disorders confirms the reliability of uGn 
for reflecting serum levels. Moreover, ROC analysis 
confirmed that there is a strong correlation between 
uGn excretion and peak LH peak following LHRH 
stimulation test with high sensitivity and specificity, 
leading to the possibility that, although peak LH is 
commonly used to detect true puberty, uLH:UCr may 
become a useful alternative non-invasive method with 
a high diagnostic value.
The range of values for uLH:uCr and uFSH:uCr 
was very wide in those cases who had pubertal delay 
and the clinical utility of uGn would be question-
able in that clinical scenario. However, in those with 
true puberty, uGn excretion was significantly higher 
than what would be expected in healthy pre-pubertal 
children, and in those cases of puberty who were 
on GnRH-a therapy, the mean uGn excretion was 
clearly within the pre-pubertal reference range. The 
clear fall in urinary excretion after initiating therapy 
suggests that this test could be used to monitor and 
titrate therapy more objectively than simple clinical 
examination and assessment of growth rate. Regular 
blood tests to check basal oestradiol and gonadotophins 
in combination with pelvic ultrasound and bone age 
assessment are often recommended to identify cases 
of progressive CPP.7 Prospective studies are now 
required to confirm the role of uGn instead of serum 
gonadotrophins for monitoring adequacy of treatment. 
It is possible that the wide range of values in the 
delayed puberty group reflected the non-standardised 
timing of the collection of the urine samples, given 
that uGn concentrations would have been expected 
to have been higher in the morning samples rather 
than those collected later in the day.17,19 Nocturnal 
pulsatile secretion of gonadotrophins starts about 
two years before physical manifestations of pubertal 
onset and would have been more effectively detected 
in the first morning urine samples.1,20
However, the non-standardised collection utilised 
did not restrict the usefulness of uGn in the assessment 
of early or precocious puberty. The female patient 
with the highest values of gonadotrophins both in 
blood and urine was diagnosed as having primary 
ovarian failure, confirming the hypothesis that uGn 
could be a useful method to differentiate and screen 
a range of disorders of the HPG axis. Recent reports 
in children with early puberty have suggested that 
uGn excretion can differentiate between those with 
slowly-progressive and rapidly-progressive preco-
cious puberty.21
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The value of performing LHRH stimulation in 
all suspected cases of early puberty has been ques-
tioned recently21 and it would indeed be beneficial to 
consider a more convenient alternative or screening 
test. In the current study, there was the impression 
that uGn excretion was higher in those with true 
puberty, characterised by a peak LH of >5U/L on 
LHRH stimulation, compared to other cases with 
early puberty with a peak LH of <5U/L; however, 
the number of cases in the latter group were not high 
enough to statistically confirm this difference.
It is possible that uLH:uCr and uFSH:uCr have 
different clinical utilities. For instance, while uLH:uCr 
concentration may have a role in distinguishing CPP 
from other forms of early puberty,22,23 the uFSH:uCr 
assessment may be useful for identifying cases of 
germ cell failure such as primary ovarian failure and 
Sertoli cell dysfunction.24-26 ULH:uFSH ratio may 
also be a useful parameter in cases of early puberty 
to differentiate between different forms of puberty, 
but this requires further exploration. In the current 
study, the groups of boys and girls studied had a 
wide range of pathologies and future studies should 
consider studying homogenous groups; standardizing 
the data for age and sex will also increase the utility 
of this tool.
In summary, this preliminary study suggests that 
uGn excretion may be a valuable method of differen-
tiating between pre-pubertal and pubertal children and 
its measurement could also be used for non-invasive 
monitoring of the effectiveness of GnRH-a therapy. 
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